12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FG-3019: Phase II expanded

FibroGen expanded an open-label Phase II trial evaluating 15 mg/kg IV FG-3019 given every 3 weeks for 45 weeks to add a second arm of 30 patients to receive 30 mg/kg FG-3019. Patients who received the initial 15 mg/kg dose who appear stable or...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >